ABBV: Other company developments

Item 8.01. Other Events. On August 18, 2026, AbbVie Inc. (“ AbbVie ”) completed its previously announced underwritten public offering (the “ Notes Offering ”) of $500,000,000 aggregate principal amount of its senior floating rate notes due 2028 (the “ Floating Rate Notes ”), $1,000,000,000 aggregate principal amount of its 4.500% senior notes due 2028 (the “ 2028 Notes ”), $1,250,000,000 aggregate principal amount of its 4.650% senior notes due 2030 (the “ 2030 Notes ”), $1,500,000,000 aggregate principal amount of its 4.875% senior notes due 2031 (the “ 2031 Notes ”), $1,250,000,000 aggregate principal amount of its 5.050% senior notes due 2033 (the “ 2033 Notes ”), $1,500,000,000 aggregate principal amount of its 5.300% senior notes due 2036 (the “ 2036 Notes ”), $1,000,000,000 aggregate principal amount of its 5.450% senior notes due 2038 (the “ 2038 Notes ”), $1,500,000,000 aggregate principal amount of its 6.000% senior notes due 2056 (the “ 2056 Notes ”) and $500,000,000 aggregate principal amount of its 6.100% senior notes due 2066 (the “ 2066 Notes ” and, together with the 2028 Notes, the 2030 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes, the 2038 Notes and the 2056 Notes, the “Fixed Rate Notes” and, collectively with the Floating Rate Notes, the “ Notes ”). The offering of each series of Notes was registered under the Securities Act of 1933, as amended (the “ Act ”), pursuant to AbbVie’s registration statement on Form S-3ASR (File No. 333-284980) (the “ Registration Statement ”) dated as of February 14, 2025. The terms of the Notes are further described in AbbVie’s prospectus supplement dated August 4, 2026, as filed with the Securities and Exchange Commission pursuant to Rule 424(b)(5) of the Act on August 6, 2026. The Notes are governed by the Indent